About 4th Annual Pharma Market Access and Pricing Asia

  1. Home
  2. About 4th Annual Pharma Market Access and Pricing Asia

The drug prices and pharmaceutical spend are on the rise, so is the demand for value-based pricing, and the Asia Pacific is seeing several drug pricing and reimbursement reforms; how are manufacturing companies justifying their costs of therapeutics development vs. patient benefit they provide?

The 4th Annual Market Access and Pricing Asia conference envisions the outlook of APAC markets and to increase manufacturers’ visibility and understanding of evolving needs of the payer, provider, and patient, and aligned market access strategy that translates APAC market dynamics to solid insights.

Part of 7th PharmaCon Asia, and 3 co-located events designed to provide maximum exposure of Asian pharma markets; leading pharma to share compelling case studies on setting the right price in the right region that satisfies regulatory agencies and meets profitability.

Conference Highlights

  • Co-Located with 3 other conferences
  • 150+ global, regional and local companies
  • Pick-and-choose your sessions and network across all 4 events
  • Online Business Partnering tool to facilitate business networks

2020 Highlights:

  • Asia Pacific health economic outlook
  • ASEAN spotlight – regulatory, procurement, and strategic pricing roadmap
  • Regional governments pricing strategies for reimbursed drug to contain rising healthcare costs
  • Emerging markets pharma spending and market access
  • Biosimilars and biologics Asian market access and pricing
  • Advanced therapeutics – Cell and gene therapies market access
  • Oncology and combination therapies outlook, price and reimbursement
  • Legal landscapes on drug assessment, reimbursement and manufacturing
  • Contracting and payment models
  • Big data, machine learning and AI for RWE outcomes
  • Smart pharmacovigilance management: AI and ML applications for safety data sources and adverse event reports
  • Regional governments and pharmaceuticals’ perspectives on affordability
  • Product launch excellence in disrupted market – traditional, current and future
  • Healthcare cost policies reforms, reimbursement, and pricing strategies
  • HTA and RWE technology and innovations case studies
  • Pharma Market Analysts’ Roundtable: Policies, Price, Products, and Procurement
  • International Pricing Index (IPI) – Touchpoints on APAC, price, investment and drug development